Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab

Progressive multifocal leukoencephalopathy (PML) is increasingly being reported in patients undergoing immunotherapy. We report a case of progressive multifocal leukoencephalopathy after treatment with nivolumab, a PD-1 blocker that is used to restore impaired T-cell responses in patients with cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Martinot, Martin, Ahle, Guido, Petrosyan, Inesa, Martinez, Camille, Gorun, Dragos M., Mohseni-Zadeh, Mahsa, Fafi-Kremer, Samira, Tebacher-Alt, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2018
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6056118/
https://www.ncbi.nlm.nih.gov/pubmed/30016251
http://dx.doi.org/10.3201/eid2408.180460
Descripción
Sumario:Progressive multifocal leukoencephalopathy (PML) is increasingly being reported in patients undergoing immunotherapy. We report a case of progressive multifocal leukoencephalopathy after treatment with nivolumab, a PD-1 blocker that is used to restore impaired T-cell responses in patients with cancer and infections. Data for 4 other cases were obtained from pharmacovigilance databases.

Ejemplares similares